Do Wall Street Analysts Like Edwards Lifesciences Stock?
Written by Emily J. Thompson, Senior Investment Analyst
Updated: May 14 2025
0mins
Source: NASDAQ.COM
Company Overview and Performance: Edwards Lifesciences Corporation, with a market cap of $44.3 billion, specializes in advanced cardiovascular disease treatments but has underperformed the broader market over the past year, with a 10.9% decline compared to the S&P 500's 12.7% gain. However, following strong Q1 2025 results showing a 6.2% sales increase, its stock rose 6.6%.
Analyst Ratings and Future Outlook: The consensus rating for Edwards Lifesciences is a "Moderate Buy" based on 28 analysts, with price targets suggesting potential upside. Analysts expect adjusted EPS to rise 1.2% year-over-year for fiscal 2025, with total sales projected between $5.7 billion and $6.1 billion.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy EW?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on EW
Wall Street analysts forecast EW stock price to rise
24 Analyst Rating
16 Buy
8 Hold
0 Sell
Moderate Buy
Current: 81.690
Low
84.00
Averages
96.52
High
105.00
Current: 81.690
Low
84.00
Averages
96.52
High
105.00
About EW
Edwards Lifesciences Corporation is the global structural heart company. The Company partners with clinicians and researchers and invests in research and development to improve care for those impacted by structural heart disease. Its product categories include Transcatheter Aortic Valve Replacement (TAVR), Transcatheter Mitral and Tricuspid Therapies (TMTT), and Surgical Structural Heart. It provides transcatheter heart valve replacement technologies designed for the minimally-invasive replacement of aortic heart valves. TAVR category includes the Edwards SAPIEN 3, the Edwards SAPIEN 3 Ultra and the Edwards SAPIEN 3 Ultra RESILIA systems. TMTT category includes the PASCAL Precision transcatheter repair system, EVOQUE tricuspid valve replacement system and Cardioband tricuspid valve reconstruction system. Its INSPIRIS RESILIA aortic valve, offers RESILIA tissue and VFit technology. It is managed in various geographical regions, such as United States, Europe, Japan and Rest of World.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Intuitive Surgical Acquires European Distribution Business
- Acquisition of European Business: Intuitive Surgical has completed the acquisition of distribution businesses from ab medica, Abex, and Excelencia Robótica, enabling direct operations in Italy, Spain, and Portugal, which is expected to enhance the company's competitiveness in the European market.
- Market Integration and Leadership: Following the acquisition, operations have been integrated into ISRG's European commercial organization, led by Senior Vice President Dirk Barten, aimed at improving customer responsiveness and market adaptability.
- Surgical System Growth: By the end of 2025, ISRG's installed base of da Vinci surgical systems in Italy, Spain, and Portugal will exceed 470 units, with the Ion platform recently launched in Italy and Spain, indicating ongoing growth potential in the European market.
- Optimistic Market Outlook: The European surgical robots market is projected to grow from $2.10 billion in 2024 to $5.21 billion by 2031, with a CAGR of 14%, and ISRG is well-positioned to benefit from this growth due to its strong market presence.
See More
Edwards Lifesciences Advances Heart Health Initiatives
- Global Health Initiative: Edwards Lifesciences announced its renewed vision for the Every Heartbeat Matters initiative, aiming to help 2 million patients facing barriers access lifesaving structural heart treatments by 2030, highlighting the company's commitment to improving heart disease patients' lives.
- Longstanding Leadership: For nearly 70 years, Edwards has focused on enhancing the lives of patients with structural heart disease through breakthrough innovations and world-class clinical expertise, demonstrating its leadership in the global healthcare ecosystem.
- Charitable Impact: Since 2014, the Every Heartbeat Matters initiative and its charitable partners have impacted over 4 million underserved structural heart patients globally, showcasing the company's efforts to break down economic and geographic barriers.
- Patient-Centric Innovation: Edwards Lifesciences is dedicated to eliminating financial, systemic, and geographic barriers faced by structural heart patients through collaboration with global partners, ensuring more patients can access care that can change their life trajectories.
See More
ORBIMED Reduces Stake in Terns Pharmaceuticals
- Share Reduction Transaction: According to a SEC filing dated February 17, 2026, ORBIMED Advisors LLC sold 5,409,671 shares of Terns Pharmaceuticals for approximately $125 million, indicating a potential decrease in confidence regarding the company's future prospects.
- Holding Changes: Following this sale, ORBIMED retains 2,153,300 shares of Terns, with a value decrease of $30.20 million, reflecting fluctuations in market expectations for its clinical pipeline.
- Market Performance: As of February 17, 2026, Terns' stock price stood at $39.58, marking an 858.4% increase over the past year, significantly outperforming the S&P 500 by 862.96 percentage points, showcasing strong market confidence in its biotech potential.
- Investor Focus: With upcoming clinical data releases, investors should monitor Terns' cash flow and trial results to assess whether its pipeline justifies the current high valuation, especially since robust data is crucial for sustaining valuation in the biotech sector.
See More
ORBIMED Reduces Stake in Terns Pharmaceuticals
- Stake Reduction Size: ORBIMED Advisors LLC disclosed in an SEC filing on February 17, 2026, that it reduced its stake in Terns Pharmaceuticals by 5,409,671 shares, with an estimated transaction size of $125.01 million, reflecting a cautious outlook on the company's future prospects.
- Position Value Change: Following this transaction, ORBIMED's position in Terns decreased to 2,153,300 shares, with a value drop of $30.20 million, indicating the market's sensitivity to fluctuations in the company's stock price.
- Asset Management Proportion: After the reduction, Terns now represents 1.78% of ORBIMED's reportable AUM, falling outside the top five holdings, which suggests a diminished significance in the investment portfolio.
- Market Performance Comparison: As of February 17, 2026, Terns' stock price stood at $39.58, reflecting an 858.4% increase over the past year, significantly outperforming the S&P 500 by 862.96 percentage points, demonstrating strong market confidence in its clinical pipeline.
See More
Edwards Lifesciences Antitrust Investigation Concluded
- Investigation Concluded: The European Commission announced the conclusion of its antitrust investigation into Edwards Lifesciences after the company withdrew its anti-copycatting policy, indicating improved compliance in market regulation.
- Policy Impact Analysis: The investigation primarily focused on how Edwards' Global Unilateral Pro-Innovation Policy affected the Transcatheter Aortic Valve Implantation (TAVI) market by limiting physicians' ability to engage in clinical studies, highlighting the company's dominant market position.
- Positive Market Reaction: Following the investigation's conclusion, Edwards Lifesciences' stock rose approximately 5%, reflecting increased investor confidence in the company's compliance and future market performance, potentially facilitating further growth in the TAVI market.
- Future Growth Outlook: Edwards Lifesciences projects an 8% to 10% sales growth for 2026, with earnings per share guidance of $2.90 to $3.05, demonstrating strong growth potential in the medical device sector.
See More
Investment Opportunities in Asian Small-Cap Stocks
- Small-Cap Appeal: Amid modest gains in Chinese stocks and economic shifts in Japan, small-cap companies are gaining attention, particularly those aligning with current economic conditions, indicating rising investor interest in this segment.
- Cogstate Performance Boost: Cogstate anticipates a revenue of A$26.9 million for the first half of 2026, reflecting a 12% increase from prior projections, showcasing strong performance in clinical trials and insider confidence.
- Semirara Coal and Power: Semirara Mining and Power generates approximately ₱41.39 billion from coal and ₱24.11 billion from power, and despite risks from external borrowing, insider stock purchases indicate confidence in future growth prospects.
- ESR-REIT Recovery: ESR-REIT reported sales of S$446 million and a net income of S$32 million for 2025, rebounding from significant losses, with projected annual growth exceeding 32%, although it still relies on external financing.
See More
Intuitive Surgical Acquires European Distribution Business
- Acquisition of European Business: Intuitive Surgical has completed the acquisition of distribution businesses from ab medica, Abex, and Excelencia Robótica, enabling direct operations in Italy, Spain, and Portugal, which is expected to enhance the company's competitiveness in the European market.
- Market Integration and Leadership: Following the acquisition, operations have been integrated into ISRG's European commercial organization, led by Senior Vice President Dirk Barten, aimed at improving customer responsiveness and market adaptability.
- Surgical System Growth: By the end of 2025, ISRG's installed base of da Vinci surgical systems in Italy, Spain, and Portugal will exceed 470 units, with the Ion platform recently launched in Italy and Spain, indicating ongoing growth potential in the European market.
- Optimistic Market Outlook: The European surgical robots market is projected to grow from $2.10 billion in 2024 to $5.21 billion by 2031, with a CAGR of 14%, and ISRG is well-positioned to benefit from this growth due to its strong market presence.
See More
Edwards Lifesciences Advances Heart Health Initiatives
- Global Health Initiative: Edwards Lifesciences announced its renewed vision for the Every Heartbeat Matters initiative, aiming to help 2 million patients facing barriers access lifesaving structural heart treatments by 2030, highlighting the company's commitment to improving heart disease patients' lives.
- Longstanding Leadership: For nearly 70 years, Edwards has focused on enhancing the lives of patients with structural heart disease through breakthrough innovations and world-class clinical expertise, demonstrating its leadership in the global healthcare ecosystem.
- Charitable Impact: Since 2014, the Every Heartbeat Matters initiative and its charitable partners have impacted over 4 million underserved structural heart patients globally, showcasing the company's efforts to break down economic and geographic barriers.
- Patient-Centric Innovation: Edwards Lifesciences is dedicated to eliminating financial, systemic, and geographic barriers faced by structural heart patients through collaboration with global partners, ensuring more patients can access care that can change their life trajectories.
See More
ORBIMED Reduces Stake in Terns Pharmaceuticals
- Share Reduction Transaction: According to a SEC filing dated February 17, 2026, ORBIMED Advisors LLC sold 5,409,671 shares of Terns Pharmaceuticals for approximately $125 million, indicating a potential decrease in confidence regarding the company's future prospects.
- Holding Changes: Following this sale, ORBIMED retains 2,153,300 shares of Terns, with a value decrease of $30.20 million, reflecting fluctuations in market expectations for its clinical pipeline.
- Market Performance: As of February 17, 2026, Terns' stock price stood at $39.58, marking an 858.4% increase over the past year, significantly outperforming the S&P 500 by 862.96 percentage points, showcasing strong market confidence in its biotech potential.
- Investor Focus: With upcoming clinical data releases, investors should monitor Terns' cash flow and trial results to assess whether its pipeline justifies the current high valuation, especially since robust data is crucial for sustaining valuation in the biotech sector.
See More
ORBIMED Reduces Stake in Terns Pharmaceuticals
- Stake Reduction Size: ORBIMED Advisors LLC disclosed in an SEC filing on February 17, 2026, that it reduced its stake in Terns Pharmaceuticals by 5,409,671 shares, with an estimated transaction size of $125.01 million, reflecting a cautious outlook on the company's future prospects.
- Position Value Change: Following this transaction, ORBIMED's position in Terns decreased to 2,153,300 shares, with a value drop of $30.20 million, indicating the market's sensitivity to fluctuations in the company's stock price.
- Asset Management Proportion: After the reduction, Terns now represents 1.78% of ORBIMED's reportable AUM, falling outside the top five holdings, which suggests a diminished significance in the investment portfolio.
- Market Performance Comparison: As of February 17, 2026, Terns' stock price stood at $39.58, reflecting an 858.4% increase over the past year, significantly outperforming the S&P 500 by 862.96 percentage points, demonstrating strong market confidence in its clinical pipeline.
See More
Edwards Lifesciences Antitrust Investigation Concluded
- Investigation Concluded: The European Commission announced the conclusion of its antitrust investigation into Edwards Lifesciences after the company withdrew its anti-copycatting policy, indicating improved compliance in market regulation.
- Policy Impact Analysis: The investigation primarily focused on how Edwards' Global Unilateral Pro-Innovation Policy affected the Transcatheter Aortic Valve Implantation (TAVI) market by limiting physicians' ability to engage in clinical studies, highlighting the company's dominant market position.
- Positive Market Reaction: Following the investigation's conclusion, Edwards Lifesciences' stock rose approximately 5%, reflecting increased investor confidence in the company's compliance and future market performance, potentially facilitating further growth in the TAVI market.
- Future Growth Outlook: Edwards Lifesciences projects an 8% to 10% sales growth for 2026, with earnings per share guidance of $2.90 to $3.05, demonstrating strong growth potential in the medical device sector.
See More
Investment Opportunities in Asian Small-Cap Stocks
- Small-Cap Appeal: Amid modest gains in Chinese stocks and economic shifts in Japan, small-cap companies are gaining attention, particularly those aligning with current economic conditions, indicating rising investor interest in this segment.
- Cogstate Performance Boost: Cogstate anticipates a revenue of A$26.9 million for the first half of 2026, reflecting a 12% increase from prior projections, showcasing strong performance in clinical trials and insider confidence.
- Semirara Coal and Power: Semirara Mining and Power generates approximately ₱41.39 billion from coal and ₱24.11 billion from power, and despite risks from external borrowing, insider stock purchases indicate confidence in future growth prospects.
- ESR-REIT Recovery: ESR-REIT reported sales of S$446 million and a net income of S$32 million for 2025, rebounding from significant losses, with projected annual growth exceeding 32%, although it still relies on external financing.
See More
